IRLAB Therapeutics Gains the Swedish Medical Products Agency’s Approval to Initiate P-I Trial of IRL757 for Apathy
Shots:
- The P-I trial (to be funded by The Michael J. Fox Foundation for Parkinson’s Research) aims at assessing the safety, tolerability & PK profile of IRL757 among healthy participants in two parts where 1st part administers single ascending doses & the 2nd part administers multiple ascending doses (MAD). Additionally, will document impact of concomitant food intake
- The drug has demonstrated the ability to prevent disruptions in the nerve signaling between the cerebral cortex and deeper brain parts across various preclinical models of cognitive function, addressing apathy
- Furthermore, the company plans to conclude the trial at the end of 2024 with the topline data anticipated in Q1’25
Ref: IRLAB Therapeutics | Image:IRLAB Therapeutics
Related News:- Ipsen Signs an Exclusive WW License Agreement with IRLAB for Mesdopetam to Treat Parkinson Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
